Literature DB >> 9701676

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

M Eriksdotter Jönhagen1, A Nordberg, K Amberla, L Bäckman, T Ebendal, B Meyerson, L Olson, M Shigeta, E Theodorsson, M Viitanen, B Winblad, L O Wahlund.   

Abstract

Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer's disease. We have treated 3 patients with Alzheimer's disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient. The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques. Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements. The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration. When stopping the NGF infusion, the pain disappeared within a couple of days. Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol. Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701676     DOI: 10.1159/000017069

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  108 in total

Review 1.  Cytokine/neurotrophin interaction in the aged central nervous system.

Authors:  N J Macdonald; F Decorti; T C Pappas; G Taglialatela
Journal:  J Anat       Date:  2000-11       Impact factor: 2.610

Review 2.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 3.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 4.  The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease.

Authors:  Josiane Budni; Tatiani Bellettini-Santos; Francielle Mina; Michelle Lima Garcez; Alexandra Ioppi Zugno
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

5.  Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

Authors:  J Winkler; G A Ramirez; L J Thal; J J Waite
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

6.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 7.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 8.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

9.  Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury.

Authors:  Antonio Chiaretti; Marco Piastra; Giancarlo Polidori; Concezio Di Rocco; Elena Caresta; Alessia Antonelli; Tiziana Amendola; Luigi Aloe
Journal:  Intensive Care Med       Date:  2003-07-05       Impact factor: 17.440

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.